Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia-Reference-Cited by-同舟云学术

Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia

Published:2018-02-22 Issue:8 Volume:131 Page:855-863
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Chen Christine¹²,Siegel David³,Gutierrez Martin³,Jacoby Meagan⁴,Hofmeister Craig C.⁵^ORCID,Gabrail Nashat⁶,Baz Rachid⁷^ORCID,Mau-Sorensen Morten⁸,Berdeja Jesus G.⁹,Savona Michael¹⁰^ORCID,Savoie Lynn¹¹,Trudel Suzanne¹²,Areethamsirikul Nuchanan¹²,Unger T. J.¹²,Rashal Tami¹²,Hanke Tim¹²,Kauffman Michael¹²,Shacham Sharon¹²,Reece Donna¹²

Affiliation:

1. Division of Medical Oncology & Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada;

2. The University of Toronto, Toronto, ON, Canada;

3. Department of Hematology, John Theurer Cancer Center, Hackensack, NJ;

4. Siteman Cancer Center, Washington University in Saint Louis, Saint Louis, MO;

5. Department of Internal Medicine, Division of Hematology, The Ohio State University, Columbus, OH;

6. Gabrail Cancer Institute, Canton, OH;

7. Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL;

8. Department of Oncology, Rigshospitalet, Copenhagen, Denmark;

9. Blood Cancer Research Program, Sarah Cannon Research Institute, Nashville, TN;

10. Division of Hematology & Oncology, Vanderbilt-Ingram Cancer Center/Vanderbilt University Medical Center, Nashville, TN;

11. Tom Baker Cancer Centre Division of Hematology, University of Calgary, Calgary, AB, Canada; and

12. Karyopharm Therapeutics Inc, Newton, MA

Abstract

Key Points Selinexor is an oral XPO1 inhibitor with antimyeloma activity. The RP2D is 45 mg/m2 (80 mg) selinexor plus 20 mg dexamethasone given twice weekly.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/131/8/855/1466500/blood797886.pdf

Reference38 articles.

1. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012;Ferlay;Int J Cancer,2015

2. Current treatment landscape for relapsed and/or refractory multiple myeloma;Dimopoulos;Nat Rev Clin Oncol,2015

3. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial;Lonial;Lancet,2016

4. Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma;Kumar;Blood,2015

5. Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma;Wolf;Leuk Lymphoma,2012

Cited by 100 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real World Efficacy and Toxicity of Selinexor: Importance of Patient Characteristics, Dose Intensity and Post Progression Outcomes;Clinical Lymphoma Myeloma and Leukemia;2023-11

2. The synergy of the XPO1 inhibitors combined with the BET inhibitor INCB057643 in high-grade B-cell lymphoma via downregulation of MYC expression;Scientific Reports;2023-10-29

3. NPM1-fusion proteins promote myeloid leukemogenesis through XPO1-dependent HOX activation;2023-10-16

4. CK1δ and CK1ε Signaling Sustains Mitochondrial Metabolism and Cell Survival in Multiple Myeloma;Cancer Research;2023-09-13

5. Nuclear Transport Inhibitors;Therapeutic Strategies in Veterinary Oncology;2023-08-23